|
| Human Siglec-5/CD170 Protein (LTP10869) |
|
| LTP10869 |
|
| 100ug |
|
|
$316 In stock |
| Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1. |
| Recombinant Human Siglec-5/CD170 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Glu17-Thr434. |
|
| Siglec-5/CD170 |
|
| Human |
|
| O15389 |
|
| Glu17-Thr434 |
|
| The protein has a predicted MW of 73.1 kDa. Due to glycosylation, the protein migrates to 90-115 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
